期刊
METABOLIC BRAIN DISEASE
卷 37, 期 4, 页码 989-1001出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-022-00911-y
关键词
Alzheimer's disease; Cognitive impairment; Sodium Tanshinone IIA Sulfonate; GLUT1; LRP1
资金
- Guangdong Provincial Key Laboratory of Research on Emergency in TCM [2017B030314176]
- Natural Science Foundation of Guangdong [2018A0303130053, 2021A1515011478]
This study found that STS can improve learning and memory abilities in APP/PS1 mice and ameliorate AD pathology through multiple pathways, including reducing oxidative stress levels, enhancing antioxidant enzyme activity, inhibiting acetylcholinesterase activity, and increasing the expression of synaptic-related proteins.
Alzheimer's disease (AD) is a most common neurodegenerative disease. Sodium Tanshinone IIA Sulfonate (STS) has been reported to ameliorate AD pathology. However, the underlying mechanism is still unclear. In this study, AD transgenic mouse model (APP/PS1) was used to explore the potential mechanism of STS against AD. Morris water maze and Y-maze tests showed that administration of STS improved learning and memory abilities of APP/PS1 mice. STS reduced the levels of reactive oxygen species and malondialdehyde, while improved the activity of superoxide dismutase in both hippocampus and cortex in APP/PS1 mice. STS inhibited the activity of acetylcholinesterase, while improved the activity of choline acetyltransferase in APP/PS1 mice. In addition, STS elevated the protein expressions of neurotrophic factors and synapse-related proteins in both the hippocampus and cortex in APP/PS1 mice. At last, STS improved the protein expressions of glucose transporter 1 (GLUT1) and low-density lipoprotein receptor-related protein 1 (LRP1). These results indicated that the potential mechanism of STS on AD might be related to A beta transportation function via GLUT1/LRP1 pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据